VSV-GPM

N/A

Report date: 2023/12/08 14:28:45

Base Information

Drug NameVSV-GPM
Drug Alias NameVesicular stomatitis oncolytic virus (China Grand Pharmaceutical and Helathcare/Shanghai Revolmmune Therapeutics Biotechnology)VSV GPM (China Grand Pharmaceutical/Revolmmune)REV-001(China Grand Pharmaceutical/Revolmmune)
ClassificationCell and gene therapy > Gene therapyBiologics > Oncolytic virus
Mechanisms of ActionImmunologic cytotoxicityCell death stimulantsGTPase Ras inhibitors
TargetsGTPase Ras
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Revolmmune Therapeutics Bio-technology Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChina Grand Pharmaceutical And Healthcare Holdings LtdShanghai Revolmmune Therapeutics Bio-technology LtdGrand Pharmaceutical （China） Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A